June 3, 2024 · Form 4 insider transaction
Griffin Stephen D. bought 96,525 shares of Anika Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Represents a 10% premium above the closing price of Anika's common stock on the date of grant.; The premium priced stock options vest in three equal annual installments beginning on June 3, 2025.